Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1

Kyle G. Rodino, David R. Peaper, Brendan J. Kelly, View ORCID ProfileFrederic Bushman, Andrew Marques, Hriju Adhikari, Zheng Jin Tu, Rebecca Marrero Rolon, Lars F. Westblade, Daniel A. Green, Gregory J. Berry, Fann Wu, Medini K. Annavajhala, Anne-Catrin Uhlemann, Bijal A. Parikh, Tracy McMillen, Krupa Jani, N. Esther Babady, Anne M. Hahn, Robert T. Koch, Nathan D. Grubaugh, Yale SARS-CoV-2 Genomic Surveillance Initiative, Daniel D. Rhoads
doi: https://doi.org/10.1101/2022.04.25.22274187
Kyle G. Rodino
1Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Kyle.rodino@pennmedicine.upenn.edu
David R. Peaper
2Department of Laboratory Medicine, Yale University, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brendan J. Kelly
3Division of Infectious Diseases, Department of Medicine and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic Bushman
4Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frederic Bushman
Andrew Marques
4Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hriju Adhikari
4Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Jin Tu
5Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Marrero Rolon
6Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars F. Westblade
6Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
7Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel A. Green
8Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory J. Berry
8Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fann Wu
8Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Medini K. Annavajhala
9Division of Infectious Diseases, Columbia University Irving Medical Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne-Catrin Uhlemann
9Division of Infectious Diseases, Columbia University Irving Medical Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bijal A. Parikh
10Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tracy McMillen
11Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krupa Jani
11Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Esther Babady
11Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
12Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M. Hahn
13Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert T. Koch
13Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan D. Grubaugh
13Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut
14Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel D. Rhoads
5Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio
15Department of Pathology, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio
16Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Mutations in the viral genome of SARS-CoV-2 can impact the performance of molecular diagnostic assays. In some cases, such as S gene target failure, the impact can serve as a unique indicator of a particular SARS-CoV-2 variant and provide a method for rapid detection. Here we describe partial ORF1ab gene target failure (pOGTF) on the cobas® SARS-CoV-2 assays, defined by a ≥2 thermocycles delay in detection of the ORF1ab gene compared to the E gene. We demonstrate that pOGTF is 97% sensitive and 99% specific for SARS-CoV-2 lineage BA.2.12.1, an emerging variant in the United States with spike L452Q and S704L mutations that may impact transmission, infectivity, and/or immune evasion. Increasing rates of pOGTF closely mirrored rates of BA.2.12.1 sequences uploaded to public databases, and, importantly increasing local rates of pOGTF also mirrored increasing overall test positivity. Use of pOGTF as a proxy for BA.2.12.1 provides faster tracking of the variant than whole-genome sequencing and can benefit laboratories without sequencing capabilities.

Competing Interest Statement

DDR has had or anticipates having agreements through his affiliated institution for research projects from the following industry sponsors: Altona, BD, bioMerieux, Cepheid, Cleveland Diagnostics, Luminex, HelixBind, Hologic, Qiagen, Q-Linea, Roche, SpecificDx, Talis, Thermo Fisher, and Vela. DDR has recently served or does serve as a scientific advisor for DiaSorin/Luminex, Renascent Diagnostics, Roche, and Talis Biomedical. No industry funding supported DDR's work on this study. LFW has received consulting fees from Roche Molecular Systems, Shionogi, and Talis Biomedical and has received research funding from Accelerate Diagnostics, BioFire Diagnostics, Hardy Diagnostics, and Roche Molecular Systems. RMR participated in as Sub investigator in a clinical trial for Qiagen. Funds received by the institution where the trial was performed. NDG is a consultant for Tempus Labs and the National Basketball Association for work related to COVID-19 but is outside the submitted work. ACU receives research funding from Merck; unrelated to the current study.

Clinical Protocols

https://github.com/bjklab/SARS-CoV-2_Ct_report.

Funding Statement

KGR, BJK, FB, AM acknowledge funding provided by a contract award from the Centers for Disease Control and Prevention (CDC BAA 200-2021-10986 and 75D30121C11102/000HCVL1-2021-55232), philanthropic donations to the Penn Center for Research on Coronaviruses and Other Emerging Pathogens, and in part by NIH grant R61/33-HL137063 and AI140442 -supplement for SARS-CoV-2. Additional assistance was provided by the Penn Center for AIDS Research (P30-AI045008) and in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00015. BJK is also supported by NIH K23 AI121485. DAG, GJB, FW, MKA, ACU acknowledge in part NIH funding (U01 DA053949). DDR and TZ acknowledge the Ohio Department of Health for its support of Cleveland Clinic's SARS-CoV-2 genomic surveillance. TM, KJ, NEB acknowledge funding in part through the National Institute of Heath/National Cancer Institute Cancer Center Support (Grant P30 CA008748) and Philanthropic Funds from the Burns Family. NDG acknowledges funding provided by the Centers for Disease Control and Prevention Broad Agency Announcement (75D30120C09570).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Cleveland Clinic Foundation approved #18-318, IRB of Columbia University Irving Medical Center approved #AAT0123, IRB of the University of Pennsylvania exemption #848605, IRB of Memorial Sloan Kettering approved #18-491, IRB of Weill Cornell Medicine #20-03021671, IRB of Washington University of St. Louis approved #20211131, IRB of Yale School of Public Health approved #2000031374

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All SARS-CoV-2 viral genomes have been deposited in GISAID and/or NCBI Genbank with accession numbers or viral names listed in Table S1. dEO outlier model code and sample reproducible report are available at: https://github.com/bjklab/SARS-CoV-2_Ct_report.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 28, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1
Kyle G. Rodino, David R. Peaper, Brendan J. Kelly, Frederic Bushman, Andrew Marques, Hriju Adhikari, Zheng Jin Tu, Rebecca Marrero Rolon, Lars F. Westblade, Daniel A. Green, Gregory J. Berry, Fann Wu, Medini K. Annavajhala, Anne-Catrin Uhlemann, Bijal A. Parikh, Tracy McMillen, Krupa Jani, N. Esther Babady, Anne M. Hahn, Robert T. Koch, Nathan D. Grubaugh, Yale SARS-CoV-2 Genomic Surveillance Initiative, Daniel D. Rhoads
medRxiv 2022.04.25.22274187; doi: https://doi.org/10.1101/2022.04.25.22274187
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1
Kyle G. Rodino, David R. Peaper, Brendan J. Kelly, Frederic Bushman, Andrew Marques, Hriju Adhikari, Zheng Jin Tu, Rebecca Marrero Rolon, Lars F. Westblade, Daniel A. Green, Gregory J. Berry, Fann Wu, Medini K. Annavajhala, Anne-Catrin Uhlemann, Bijal A. Parikh, Tracy McMillen, Krupa Jani, N. Esther Babady, Anne M. Hahn, Robert T. Koch, Nathan D. Grubaugh, Yale SARS-CoV-2 Genomic Surveillance Initiative, Daniel D. Rhoads
medRxiv 2022.04.25.22274187; doi: https://doi.org/10.1101/2022.04.25.22274187

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)